Symbols / AKTX
AKTX Chart
About
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.67M |
| Enterprise Value | 17.37B | Income | -15.77M | Sales | — |
| Book/sh | 0.70 | Cash/sh | 2484000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | inf | Forward P/E | -0.85 | PEG | — |
| P/S | — | P/B | 0.37 | P/C | — |
| EV/EBITDA | -1320.70 | EV/Sales | — | Quick Ratio | 0.16 |
| Current Ratio | 0.19 | Debt/Eq | 9.77 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | -0.30 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 17:00 | ROA | -34.20% |
| ROE | -197.24% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 45.78M |
| Shs Float | 43.05B | Short Float | 1.00% | Short Ratio | 0.53 |
| Short Interest | — | 52W High | 1.73 | 52W Low | 0.22 |
| Beta | 0.31 | Avg Volume | 1.09M | Volume | 540.52K |
| Target Price | $2.90 | Recom | None | Prev Close | $0.24 |
| Price | $0.26 | Change | 4.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.90
Mean price target
2. Current target
$0.26
Latest analyst target
3. DCF / Fair value
$0.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.26
Low
$1.00
High
$7.00
Mean
$2.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-05 | init | Ladenburg Thalmann | — → Buy | $1 |
| 2025-09-09 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-07-18 | init | Maxim Group | — → Buy | $5 |
- RNA splicing pioneer Olga Anczukow joins Akari cancer drug board - Stock Titan Mon, 23 Feb 2026 13
- $AKTX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 20 Feb 2026 21
- Akari Therapeutics (AKTX) Appoints New Advisory Board Member - GuruFocus Mon, 23 Feb 2026 15
- Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - simplywall.st Fri, 14 Nov 2025 08
- Akari Therapeutics to Present at Biocom Global Partnering Conference - Intellectia AI Sat, 21 Feb 2026 02
- CGTX, RVPH, SHOT, SONN, AKTX Rally After-Hours On Clinical Updates And Fed Rate Cut Momentum - Nasdaq hu, 18 Sep 2025 07
- Inside Akari's expanding oncology ADC pipeline and patent push - Stock Titan Wed, 11 Feb 2026 08
- Insiders Who Purchased US$1.81m Of Akari Therapeutics Stock May Not Have Expected 36% Tumble - Yahoo Finance ue, 23 Dec 2025 08
- Akari Therapeutics Prepares Investor Presentation for Conferences - TipRanks Mon, 08 Dec 2025 08
- Akari Therapeutics CEO Abizer Gaslightwala Discusses ADC Pipeline Expansion and Lead Program AKTX-101 in Recent Virtual Interview - Quiver Quantitative Wed, 11 Feb 2026 13
- Akari Therapeutics raises $5 million in at-market offering - Investing.com ue, 16 Dec 2025 08
- Akari Therapeutics Insiders Added US$1.79m Of Stock To Their Holdings - Yahoo Finance Wed, 16 Jul 2025 07
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 13 Feb 2026 21
- Akari Therapeutics Announces $5 Million Financing Through ADS Offering and Warrants | AKTX Stock News - Quiver Quantitative ue, 16 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 58619 | 43964 | — | Stock Award(Grant) at price 0.75 per share. | FARAG KAMEEL D | Chief Financial Officer | — | 2025-10-31 00:00:00 | D |
| 1 | 6277 | 4645 | — | Stock Award(Grant) at price 0.74 per share. | FARAG KAMEEL D | Chief Financial Officer | — | 2025-10-22 00:00:00 | D |
| 2 | 21000 | 19540 | — | Purchase at price 0.90 - 0.94 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-08-25 00:00:00 | D |
| 3 | 6146 | 7120 | — | Purchase at price 1.15 - 1.16 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-24 00:00:00 | D |
| 4 | 10000 | 12000 | — | Purchase at price 1.20 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-20 00:00:00 | D |
| 5 | 15000 | 18000 | — | Purchase at price 1.20 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-17 00:00:00 | D |
| 6 | 45000 | 54350 | — | Stock Award(Grant) at price 1.19 - 1.23 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
| 7 | 20000 | 25400 | — | Stock Award(Grant) at price 1.27 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-10 00:00:00 | D |
| 8 | 4464 | 4046 | — | Stock Award(Grant) at price 0.91 per share. | NEAL JAMES R | Director | — | 2025-03-06 00:00:00 | D |
| 9 | 892857 | 809286 | — | Stock Award(Grant) at price 0.91 per share. | HUH HOYOUNG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.63M | -16.74M | -28.52M | -17.02M |
| TotalUnusualItems | -2.90M | 6.74M | 5.44M | -193.22K |
| TotalUnusualItemsExcludingGoodwill | -2.90M | 6.74M | 5.44M | -193.22K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -19.79M | -10.01M | -17.75M | -17.42M |
| ReconciledDepreciation | 14.00K | 4.00K | 4.00K | 4.13K |
| EBITDA | -19.53M | -10.00M | -23.08M | -17.21M |
| EBIT | -19.55M | -10.01M | -23.09M | -17.21M |
| NetInterestIncome | -236.00K | 82.00K | 46.00K | 10.60K |
| InterestExpense | 244.00K | 0.00 | ||
| InterestIncome | 8.00K | 82.00K | 46.00K | 10.60K |
| NormalizedIncome | -16.89M | -16.74M | -23.18M | -17.23M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -19.79M | -10.01M | -17.75M | -17.42M |
| TotalExpenses | 16.65M | 16.81M | 23.09M | 17.21M |
| TotalOperatingIncomeAsReported | -21.64M | -16.81M | -23.09M | -17.21M |
| DilutedAverageShares | 11.94M | 4.89M | 3.12M | 2.15M |
| BasicAverageShares | 11.94M | 4.89M | 3.12M | 2.15M |
| DilutedEPS | 0.00 | 0.00 | -5.40 | -8.12 |
| BasicEPS | 0.00 | 0.00 | -5.40 | -8.12 |
| DilutedNIAvailtoComStockholders | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncomeCommonStockholders | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncome | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncomeIncludingNoncontrollingInterests | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncomeContinuousOperations | -19.79M | -10.01M | -17.75M | -17.42M |
| PretaxIncome | -19.79M | -10.01M | -17.75M | -17.42M |
| OtherIncomeExpense | -2.91M | 6.72M | 5.29M | -220.70K |
| OtherNonOperatingIncomeExpenses | -3.00K | -19.00K | -142.00K | -27.48K |
| SpecialIncomeCharges | -5.00M | 0.00 | ||
| RestructuringAndMergernAcquisition | 5.00M | 0.00 | ||
| GainOnSaleOfSecurity | 2.09M | 6.74M | 5.44M | -193.22K |
| NetNonOperatingInterestIncomeExpense | -236.00K | 82.00K | 46.00K | 10.60K |
| InterestExpenseNonOperating | 244.00K | 0.00 | ||
| InterestIncomeNonOperating | 8.00K | 82.00K | 46.00K | 10.60K |
| OperatingIncome | -16.65M | -16.81M | -23.09M | -17.21M |
| OperatingExpense | 16.65M | 16.81M | 23.09M | 17.21M |
| ResearchAndDevelopment | 6.98M | 5.45M | 9.56M | 9.13M |
| SellingGeneralAndAdministration | 9.66M | 11.36M | 13.53M | 8.08M |
| GeneralAndAdministrativeExpense | 9.66M | 11.36M | 13.53M | 8.08M |
| OtherGandA | 9.66M | 11.36M | 13.53M | 8.08M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 53.19B | 13.23B | 7.44B | 4.76B |
| ShareIssued | 53.19B | 13.23B | 7.44B | 4.76B |
| NetDebt | 661.00K | |||
| TotalDebt | 3.26M | |||
| TangibleBookValue | -25.38M | -243.00K | 1.77M | 5.53M |
| InvestedCapital | 25.49M | -229.00K | 1.79M | 5.55M |
| WorkingCapital | -16.96M | -243.00K | 1.77M | 5.53M |
| NetTangibleAssets | -25.38M | -243.00K | 1.77M | 5.53M |
| CommonStockEquity | 22.23M | -229.00K | 1.79M | 5.55M |
| TotalCapitalization | 22.23M | -229.00K | 1.79M | 5.55M |
| TotalEquityGrossMinorityInterest | 22.23M | -229.00K | 1.79M | 5.55M |
| StockholdersEquity | 22.23M | -229.00K | 1.79M | 5.55M |
| GainsLossesNotAffectingRetainedEarnings | -738.00K | -1.04M | -771.00K | -540.97K |
| OtherEquityAdjustments | -738.00K | -1.04M | -771.00K | -540.97K |
| RetainedEarnings | -247.25M | -227.46M | -217.45M | -199.71M |
| AdditionalPaidInCapital | 264.90M | 226.95M | 219.27M | 205.32M |
| CapitalStock | 5.32M | 1.32M | 745.00K | 475.97K |
| CommonStock | 5.32M | 1.32M | 745.00K | 475.97K |
| TotalLiabilitiesNetMinorityInterest | 28.33M | 4.58M | 12.04M | 6.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.42M | 0.00 | 0.00 | 0.00 |
| OtherNonCurrentLiabilities | 383.00K | |||
| NonCurrentDeferredLiabilities | 8.04M | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 8.04M | 0.00 | ||
| CurrentLiabilities | 19.91M | 4.58M | 12.04M | 6.09M |
| OtherCurrentLiabilities | 1.11M | 1.35M | 7.95M | 1.12M |
| CurrentDebtAndCapitalLeaseObligation | 3.26M | |||
| CurrentDebt | 3.26M | |||
| OtherCurrentBorrowings | 950.00K | |||
| CurrentNotesPayable | 2.31M | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 473.00K | 187.00K | 1.43M | |
| PayablesAndAccruedExpenses | 15.07M | 3.05M | 2.67M | 4.97M |
| CurrentAccruedExpenses | 2.66M | 1.38M | 1.72M | 3.18M |
| Payables | 12.41M | 1.67M | 947.00K | 1.79M |
| AccountsPayable | 12.41M | 1.67M | 947.00K | 1.79M |
| TotalAssets | 50.56M | 4.36M | 13.83M | 11.65M |
| TotalNonCurrentAssets | 47.61M | 14.00K | 17.00K | 22.93K |
| GoodwillAndOtherIntangibleAssets | 47.61M | 14.00K | 17.00K | 22.93K |
| OtherIntangibleAssets | 39.18M | 14.00K | 17.00K | 22.93K |
| Goodwill | 8.43M | |||
| NetPPE | 0.00 | |||
| AccumulatedDepreciation | -164.94K | |||
| GrossPPE | 164.94K | |||
| MachineryFurnitureEquipment | 164.94K | |||
| CurrentAssets | 2.95M | 4.34M | 13.81M | 11.63M |
| OtherCurrentAssets | 201.00K | 197.00K | 100.00K | 90.30K |
| RestrictedCash | 60.00K | 0.00 | ||
| PrepaidAssets | 92.00K | 299.00K | 465.00K | 2.17M |
| CashCashEquivalentsAndShortTermInvestments | 2.60M | 3.85M | 13.25M | 9.36M |
| CashAndCashEquivalents | 2.60M | 3.85M | 13.25M | 9.36M |
| CashFinancial | 2.60M | 3.85M | 13.25M | 9.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.55M | -16.43M | -21.50M | -18.85M |
| RepaymentOfDebt | -1.85M | 0.00 | ||
| IssuanceOfDebt | 1.00M | 0.00 | ||
| IssuanceOfCapitalStock | 11.81M | 7.02M | 25.19M | 14.29M |
| InterestPaidSupplementalData | 143.00K | 0.00 | ||
| EndCashPosition | 2.66M | 3.85M | 13.25M | 9.36M |
| BeginningCashPosition | 3.85M | 13.25M | 9.36M | 14.06M |
| EffectOfExchangeRateChanges | -4.00K | 7.00K | 105.00K | -140.73K |
| ChangesInCash | -1.18M | -9.41M | 3.78M | -4.55M |
| FinancingCashFlow | 10.99M | 7.02M | 25.29M | 14.29M |
| CashFlowFromContinuingFinancingActivities | 10.99M | 7.02M | 25.29M | 14.29M |
| ProceedsFromStockOptionExercised | 28.00K | 4.00K | 94.00K | 0.00 |
| NetCommonStockIssuance | 11.81M | 7.02M | 25.19M | 14.29M |
| CommonStockIssuance | 11.81M | 7.02M | 25.19M | 14.29M |
| NetIssuancePaymentsOfDebt | -855.00K | 0.00 | ||
| NetShortTermDebtIssuance | -855.00K | 0.00 | ||
| ShortTermDebtPayments | -1.85M | 0.00 | ||
| ShortTermDebtIssuance | 1.00M | 0.00 | ||
| InvestingCashFlow | 382.00K | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | 382.00K | 0.00 | ||
| NetBusinessPurchaseAndSale | 382.00K | 0.00 | ||
| SaleOfBusiness | 382.00K | 0.00 | ||
| OperatingCashFlow | -12.55M | -16.43M | -21.50M | -18.85M |
| CashFlowFromContinuingOperatingActivities | -12.55M | -16.43M | -21.50M | -18.85M |
| ChangeInWorkingCapital | 6.54M | -866.00K | 822.00K | -1.98M |
| ChangeInPayablesAndAccruedExpense | 5.22M | -936.00K | -877.00K | -241.31K |
| ChangeInPrepaidAssets | 1.32M | 70.00K | 1.70M | -1.74M |
| OtherNonCashItems | 271.00K | 142.00K | ||
| StockBasedCompensation | 2.25M | 1.15M | 735.00K | 314.65K |
| DepreciationAmortizationDepletion | 14.00K | 4.00K | 4.00K | 4.13K |
| DepreciationAndAmortization | 14.00K | 4.00K | 4.00K | 4.13K |
| OperatingGainsLosses | -1.83M | -6.85M | -5.32M | 242.50K |
| GainLossOnInvestmentSecurities | -2.08M | -6.60M | -4.98M | |
| NetForeignCurrencyExchangeGainLoss | 255.00K | -255.00K | -334.00K | 242.50K |
| NetIncomeFromContinuingOperations | -19.79M | -10.01M | -17.75M | -17.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AKTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|